ImmunityBio Inc
IBRXHealthcare|Biotechnology|USA
$8.23
-0.65 (-7.33%)
About
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Stock Price
+186.8%(1Y)
Pipeline Summary
89 total trials51
Phase 1
57
Phase 2
8
Phase 3
0
Phase 4
Withdrawn: 26Completed: 18Active: 11Terminated: 17Recruiting: 10NOT_YET_RECRUITING: 5AVAILABLE: 2
Active Trials (21)
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT04390399Pancreatic Cancer
Phase 2Active
Enrollment: 328 participants
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
NCT06061809Glioblastoma
Phase 2Active
Enrollment: 34 participants
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963NMIBC
Phase 1Phase 2Recruiting
Enrollment: 40 participants
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
NCT07556757B-ALL
Phase 1Recruiting
Enrollment: 10 participants
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
NCT06710288Platinum-resistant Ovarian Cancer
Phase 2Recruiting
Enrollment: 20 participants
BioScore
5.2/10
Watchlist
Ownership
Recent Insider Trades
Cohen CherylSELL
2026-07-02131,210 shares @ $9.5
Selecky ChristobelSELL
2026-07-01159,478 shares @ $9.02
Selecky ChristobelSELL
2026-06-3096,722 shares @ $9.01
Simon Barry J.SELL
2026-06-2425,000 shares @ $7.88
Simon Barry J.SELL
2026-06-0423,033 shares @ $7.18
Recent News
2026-07-02 00:03:30
2026-06-27 02:01:01
Data last updated: Jul 13, 2026, 12:39 PM